ClinicalTrials.gg
CompletedNCT04138498Updated Apr 8, 2021Results posted

CTx-1301 Comparative Bioavailability Study

A Phase 1/2 interventional study of Dexmethylphenidate 5 Mg Oral Capsule, Extended Release and Dexmethylphenidate 6.25 mg Tablet in ADHD, sponsored by Cingulate Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Cingulate Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
431st of 706
45 · median 70
Started
2019
with 31 others
Phase 1/2
14 of 807
2 open now
Registered
574th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 431st largest by enrollment of the 706 interventional ones that give a count, is one of 32 that started in 2019, is one of 14 in phase 1/2, and was the 574th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301. In addition, this study seeks to characterize the pharmacokinetics of dexmethylphenidate and evaluate the safety and tolerability of CTx-1301.

Read the detailed description

The study will comprise of a randomized, single-dose, four-sequence, four-period, in-clinic crossover study in approximately 36 adult ADHD subjects. All subjects considered eligible at Screening will proceed to tolerability test day, dosing 40 mg Focalin XR to evaluate safety and tolerability of the higher dose of d-MPH. If subject is able to safely tolerate the test dose, and meets all inclusion/exclusion criteria, they will be considered eligible for randomization into the study. All subjects will be randomized to receive four treatments throughout the course of the study; one CTx-1301 trimodal d-MPH tablet containing 6.25 mg d-MPH, one Focalin 5 mg XR capsule, one CTx-1301 50 mg tablet, and one 40 mg Focalin XR capsule. Administration of study drug will occur only on Assessment Days; no study drug will be administered during screening or unscheduled days (USVs).

The lowest and highest doses of CTx-1301 (dexmethylphenidate, 6.25 and 50 mg) were selected to bridge to the lowest and highest doses of Focalin XR (dexmethylphenidate, 5 and 40 mg) in this comparative BA study.

03

Conditions studied

  • ADHD

Keywords

  • ADHD
  • bioavailability
  • dexmethylphenidate
  • BA study
  • dMPH
  • d-MPH
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender

    a. Male or Female

  2. Age

    a. Aged between 18 and 55 years inclusive.

  3. Weight and

    1. Body weight ≥ 50 kg
    2. BMI ≥ 18 and ≤ 35
  4. Compliance

    1. Understands and is willing, able and likely to comply with all study procedures and restrictions.
    2. If sexually active, male subjects must use the double-barrier method (condom and spermicide) for during the study and for 90 days following the last administration of study drug.
    3. If sexually active, female subjects of must use an acceptable method of contraception, including abstinence from heterosexual intercourse, hormonal contraceptives, intrauterine device (IUD) with or without hormones, or double-barrier method (e.g. condom and spermicide), during the study and for 30 days following the last administration of study drug.
    4. Male subjects must agree not to donate sperm during the study and for 90 days following the last administration of study drug.
    5. Female subjects must agree not to donate eggs during the study and for 30 days following the last administration of study drug.
  5. Consent a. Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written (signed and dated) obtained before any study-related activities are performed.
  6. Indication

    1. Subject must report history of diagnosis of ADHD.
    2. If subject is currently taking stimulant medication, they must be willing and able to safely abstain from any other ADHD treatment during 96 hrs. prior to check-in on Day -4 and through the complete duration of the study.
  7. General Health

    1. Good general health (in the opinion of an investigator) with no or relevant abnormalities on medical history or physical examination which could affect the safety of the subject or study data.
    2. No vomiting or fever within 24-hours of check-in at Day -4
    3. Subject has sufficient venous access to allow cannulation and/or venipuncture to obtain the required volume of blood for this study.
    4. Subject must currently be taking or previously have taken a stimulant medication for ADHD.
  8. Smoking/Caffeine/Alcohol

    1. Subject must be able to refrain from smoking cigarettes 1 hour prior to dosing and 7 hours after dosing on dosing days. Subject must agree not to smoke more than one cigarette per hour, not to exceed 10 cigarettes per day.
    2. Subject must be able to refrain from caffeine for 10 hours prior to check-in at Day -4 and for the duration of the study.
    3. Subject must be able to refrain from using alcohol 48 hrs. prior to Day -4 and for the duration of the study.
  9. ADHD Medication History

    1. Subject's medication history suggests they will be able to tolerate a 40 mg dose of dexmethylphenidate.
    2. Subject must demonstrate tolerability of dexmethylphenidate assessed by tolerability day/test dose of 40 mg Focalin XR as evaluated by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Medical History

    1. Current and/or recurrent disease or illness that, in the opinion of an investigator, could affect the study conduct, study outcome, subject safety, or pharmacokinetic (PK) assessments (e.g., hepatic disorders, renal insufficiency, non-self-limiting gastrointestinal disorders, congestive heart failure).
    2. Current and/or previous history of any other serious, severe or unstable psychiatric illness which in the opinion of the investigator, may require treatment (e.g. anxiety, psychosis, mood disorder, motor tics or suicidality) or make the subject unlikely to fully complete the study, and/or any condition that presents undue risk from the study medication or procedures.
    3. Subject cannot have suicidal thoughts within the last 6 months as supported by the Columbia Suicide Severity Rating Scale (C-SSRS).
    4. Positive test results for (HIV)-1/HIV-2 antibodies, surface antigen (HBsAg) or virus antibody (HCVAb).
    5. A family history of sudden cardiac or unexplained death.
    6. Any condition or abnormal laboratory finding that could result in harm to the subject, affect the outcome of the study, or suggest unstable medical illness.
    7. As a result of the MINI, medical history, physical examination, and/or screening investigations (including results, vital signs and/or laboratory abnormality), an Investigator considers the subject disqualified for the study.
    8. Subject plans to undergo elective procedures/surgery at any time during the study.
    9. Subject has had surgery within the past 90 days.
    10. Subject of is pregnant or planning to become pregnant during the duration of the study or within 30 days of the end of the study.
    11. Subject is breast-feeding during the study or within 30 days of the study.
  2. Medications

    a. Subject has taken any medication that, in the opinion of an Investigator, has been shown to alter the PK of d-MPH.

    b. Use of any prescription medication within 14 days prior to Day -3 (ADHD medications must be discontinued at least 96 hours prior to check-in at Day -4), and/or use of any OTC medications (such as antacids, vitamins, minerals, dietary/herbal preparations, and nutritional supplements) within 7 days prior to Day -3 unless jointly approved by an Investigator and Sponsor.

    i. Subjects are permitted to take hormonal and hormone replacement therapy at acceptable levels if stable at least 30 days prior to Day -4, through the duration of the study, and for 30 days after the study ends.

    ii. Acetaminophen (up to 2 grams per day) may be used during the study under the direction of the Investigator.

    iii. On a case-by-case basis, an Investigator is permitted to allow the use of certain concomitant medications, for example, to treat an AE, as long as an Investigator determines that the medication will not affect the subject's safety or study integrity (eg, topical medications).

  3. Alcohol/Substance Abuse

    1. Recent history (within the last year) of alcohol or other substance abuse.
    2. Subject has positive breath alcohol test or urine test for drugs of abuse at screening or check-in (prescribed ADHD medication is acceptable during screening but must be stopped at least 96 hrs prior to check in at Day -4). Note: At the discretion of an Investigator, the tests may be repeated. If THC is positive at screening or check-in, a cannabis intoxication evaluation will be done by an investigator at check-in only; inclusion will be at the investigator's discretion, due to the slow release of THC from adipose tissue.
  4. Smoking

    a. Subject regularly smokes more than 10 cigarettes/day (or other nicotine-containing products) or Subject has recently discontinued smoking (within the last 3 months)

  5. Allergy/Intolerance

    a. Subject has a history of allergy to d-MPH, to any component of the dosage form, or any other allergy, which, in the opinion of an Investigator, contraindicates their participation.

  6. Clinical Studies

    1. Participation in another product study (inclusive of final post-study examination) or receipt of an investigational drug within the 30 days before screening day.
    2. Previous participation in this study.
  7. Personnel

    a. An employee of the sponsor, study site, or members of their immediate family.

  8. Blood

    1. Subject has donated blood, plasma, or experienced significant blood loss (excess of 500 ml) within 3 months of screening and for the duration of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Sequence 1 (ADBC)

    Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.

    Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 6.25 mg Tablet · Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 50 mg Tablet

  • Experimental
    Sequence 2 (BACD)

    Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.

    Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 6.25 mg Tablet · Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 50 mg Tablet

  • Experimental
    Sequence 3 (CBDA)

    Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.

    Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 6.25 mg Tablet · Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 50 mg Tablet

  • Experimental
    Sequence 4 (DCAB)

    Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.

    Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 6.25 mg Tablet · Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 50 mg Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    d-MPH Plasma concentration

    Time frame: Hours 0 to 28

  2. AUC(0-infinity)

    Area under the curve from time 0 extrapolated to infinite time

    Time frame: Hours 0 to 28

  3. AUC(Last)

    AUC from time 0 to the last measurable concentration

    Time frame: Hours 0 to 28

Secondary outcomes

  1. Partial AUCs

    AUC from Hours 0-3, 3-6, 6-9, 9-12, and 12 to 16

    Time frame: Hours 0 to 28

  2. K

    Rate at which a drug is removed from the system

    Time frame: Hours 0 to 28

  3. Half-life

    Time (Hours) it takes for the concentration of the drug in plasma to be reduced by 50%

    Time frame: Hours 0 to 28

  4. Tmax

    Time (Hours) after administration of a drug when the maximum plasma concentration is reached

    Time frame: Hours 0 to 28

  5. Tlag

    Delay (hours) between the time of dosing and time of appearance of concentration in the sampling

    Time frame: Hours 0 to 28

  6. Incidence of Treatment-Emergent Adverse Events

    TEAEs will be measured from Day 0 to Day 10 (End of Study)

    Time frame: Day 0 to Day 10

07

Results

Posted Apr 8, 2021

Participant flow

Subjects were recruited at a single site from November 22, 2019 to March 06, 2020.

Participant flow — Overall Study
MilestoneSequence 1 (ADBC)Sequence 2 (BACD)Sequence 3 (CBDA)Sequence 4 (DCAB)
Started11101212
Completed1010109
Not completed1023

Outcome measures

PrimaryCmax

d-MPH Plasma concentration

Time frame:
Hours 0 to 28
Reported as:
Geometric mean · pg/mL
Cmax
pg/mLTreatment ATreatment BTreatment B/ATreatment CTreatment DTreatment D/C
Cmax3138.41 (2893.862 to 3403.633)2874.52 (2646.813 to 3121.816)0.92 (0.843 to 0.995)23884.13 (22050.942 to 25869.722)24685.37 (22774.231 to 26756.894)1.03 (0.953 to 1.120)
PrimaryAUC(0-infinity)

Area under the curve from time 0 extrapolated to infinite time

Time frame:
Hours 0 to 28
Reported as:
Geometric mean · ng/mL
AUC(0-infinity)
ng/mLTreatment ATreatment BTreatment B/ATreatment CTreatment DTreatment D/C
AUC(0-infinity)24384.31 (22579.167 to 26333.776)27661.46 (25603.455 to 29884.885)1.13 (1.090 to 1.181)203127.64 (188123.507 to 219328.465)239317.53 (221590.471 to 258462.729)1.18 (1.133 to 1.225)
PrimaryAUC(Last)

AUC from time 0 to the last measurable concentration

Time frame:
Hours 0 to 28
Reported as:
Geometric mean · pg/mL
AUC(Last)
pg/mLTreatment ATreatment BTreatment B/ATreatment CTreatment DTreatment D/C
AUC(Last)22793.45 (20666.366 to 25139.474)25540.99 (23149.418 to 28179.632)1.12 (1.075 to 1.169)190456.27 (172736.598 to 209993.654)221949.48 (201261.408 to 244764.129)1.17 (1.118 to 1.214)
SecondaryPartial AUCs

AUC from Hours 0-3, 3-6, 6-9, 9-12, and 12 to 16

Time frame:
Hours 0 to 28
Reported as:
Geometric mean · hr*pg/mL
Partial AUCs
hr*pg/mLTreatment ATreatment BTreatment B/ATreatment CTreatment DTreatment D/C
AUC0-34928.24 (4520.066 to 5373.276)3943.21 (3612.595 to 4304.075).80 (0.743 to 0.861)37963.37 (34854.010 to 41350.112)32744.35 (30044.791 to 35686.470).86 (0.803 to 0.927)
AUC3-66939.76 (6357.221 to 7575.675)6317.47 (5778.203 to 6907.071)0.91 (0.831 to 0.997)51204.34 (46939.593 to 55856.559)51368.60 (47085.223 to 56041.632)1.00 (0.918 to 1.096)
AUC6-95644.67 (5176.704 to 6154.948)5624.50 (5149.945 to 6142.780)1.00 (0.909 to 1.093)49159.01 (45116.976 to 53563.164)53313.02 (48889.077 to 58137.277)1.08 (0.991 to 1.187)
AUC9-122769.68 (2498.675 to 3070.079)3638.05 (3277.387 to 4038.399)1.31 (1.198 to 1.440)25193.87 (22743.535 to 27908.203)34316.26 (30955.023 to 38042.466)1.36 (1.245 to 1.490)
AUC12-161643.22 (1458.189 to 1851.741)3092.55 (2739.223 to 3491.455)1.88 (1.679 to 2.109)15739.33 (13978.890 to 17721.462)26183.15 (23231.791 to 29509.457)1.66 (1.488 to 1.860)
SecondaryK

Rate at which a drug is removed from the system

Time frame:
Hours 0 to 28
Reported as:
Geometric mean · (1/hr)
K
(1/hr)Treatment ATreatment BTreatment CTreatment D
K0.18 ± 0.0530.16 ± 0.0400.17 ± 0.0350.16 ± 0.034
SecondaryHalf-life

Time (Hours) it takes for the concentration of the drug in plasma to be reduced by 50%

Time frame:
Hours 0 to 28
Reported as:
Geometric mean · hr*pg/mL
Half-life
hr*pg/mLTreatment ATreatment BTreatment CTreatment D
Half-life3.77 ± 1.0664.32 ± 1.8664.05 ± 0.9774.21 ± 1.163
SecondaryTmax

Time (Hours) after administration of a drug when the maximum plasma concentration is reached

Time frame:
Hours 0 to 28
Reported as:
Median · hr*pg/mL
Tmax
hr*pg/mLTreatment ATreatment BTreatment CTreatment D
Tmax5.00 (1.0 to 7.0)5.00 (1.0 to 7.0)6.00 (1.0 to 8.0)5.00 (1.0 to 10.0)
SecondaryTlag

Delay (hours) between the time of dosing and time of appearance of concentration in the sampling

Time frame:
Hours 0 to 28
Reported as:
Median · hr
Tlag
hrTreatment ATreatment BTreatment CTreatment D
Tlag0.00 (0.0 to 0.5)0.00 (0.0 to 0.5)0.00 (0.0 to 0.5)0.00 (0.0 to 0.5)
SecondaryIncidence of Treatment-Emergent Adverse Events

TEAEs will be measured from Day 0 to Day 10 (End of Study)

Time frame:
Day 0 to Day 10
Reported as:
Number · participants
Incidence of Treatment-Emergent Adverse Events
participantsTreatment ATreatment BTreatment CTreatment D
Incidence of Treatment-Emergent Adverse Events742214

Adverse events

Collected over Day -4 to Day 10. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/41 (0%)0/41 (0%)7/41 (17.1%)
Treatment B0/39 (0%)0/39 (0%)4/39 (10.3%)
Treatment C0/43 (0%)0/43 (0%)22/43 (51.2%)
Treatment D0/42 (0%)0/42 (0%)14/42 (33.3%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventTreatment ATreatment BTreatment CTreatment D
TachycardiaCardiac disorders0/410/394/433/42
HeadacheNervous system disorders0/411/393/432/42
NauseaGastrointestinal disorders1/411/391/432/42
Decreased AppetiteMetabolism and nutrition disorders0/410/391/432/42
DizzinessNervous system disorders0/410/390/432/42
AnxietyPsychiatric disorders0/410/391/432/42
InsomniaPsychiatric disorders0/410/390/432/42
IrritabilityPsychiatric disorders0/410/390/432/42
PalpitationsCardiac disorders1/410/392/430/42
Euphoric moodPsychiatric disorders1/410/392/431/42

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sequence 1 (ADBC)Sequence 2 (BACD)Sequence 3 (CBDA)Sequence 4 (DCAB)Total
<=18 years00000
Between 18 and 65 years1110121245
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1 (ADBC)Sequence 2 (BACD)Sequence 3 (CBDA)Sequence 4 (DCAB)Total
Female02125
Male118111040
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1 (ADBC)Sequence 2 (BACD)Sequence 3 (CBDA)Sequence 4 (DCAB)Total
Hispanic or Latino00235
Not Hispanic or Latino111010940
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1 (ADBC)Sequence 2 (BACD)Sequence 3 (CBDA)Sequence 4 (DCAB)Total
American Indian or Alaska Native00000
Asian10012
Native Hawaiian or Other Pacific Islander00000
Black or African American346518
White766625
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Sequence 1 (ADBC)Sequence 2 (BACD)Sequence 3 (CBDA)Sequence 4 (DCAB)Total
United States1110121245
History of ADHD
History of ADHD(participants)Sequence 1 (ADBC)Sequence 2 (BACD)Sequence 3 (CBDA)Sequence 4 (DCAB)Total
Number1110121245
08

Study locations

1 site
  • Vince & Associates
    Overland Park, Kansas 66212, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Mar 2020, 3 months.

Results were first posted in Apr 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2019
First posted
Oct 24, 2019
StartActual
Dec 6, 2019
Primary completionActual
Mar 6, 2020
CompletionActual
Mar 6, 2020
Results first posted
Apr 8, 2021
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04138498
Lead sponsor
Cingulate Therapeutics
Responsible party
Sponsor
First posted
Oct 24, 2019
Start date
Dec 6, 2019
Primary completion
Mar 6, 2020
Completion
Mar 6, 2020
Results posted
Apr 8, 2021
Last update
Apr 8, 2021

Study contacts

Matt Brams, MD
study director · Sponsor Medical Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmethylphenidate

Start the discussion